Raptor Pharmaceutical Corp. (NASDAQ:RPTP) shares traded up 2.7% during mid-day trading on Friday . The company traded as high as $6.05 and last traded at $6.02, with a volume of 362,596 shares traded. The stock had previously closed at $5.86.

A number of research analysts have recently issued reports on the stock. Wedbush reaffirmed a “neutral” rating and issued a $4.00 price objective on shares of Raptor Pharmaceutical Corp. in a research report on Thursday, April 7th. Cowen and Company reaffirmed a “buy” rating and issued a $8.00 price objective on shares of Raptor Pharmaceutical Corp. in a research report on Sunday, April 17th. FBR & Co reaffirmed a “hold” rating on shares of Raptor Pharmaceutical Corp. in a research report on Sunday, June 12th. Oppenheimer Holdings Inc. reaffirmed a “market perform” rating on shares of Raptor Pharmaceutical Corp. in a research report on Monday, April 11th. Finally, Leerink Swann reaffirmed an “outperform” rating and issued a $11.00 price objective on shares of Raptor Pharmaceutical Corp. in a research report on Tuesday, April 12th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and four have given a buy rating to the company. The company has a consensus rating of “Hold” and an average price target of $11.00.

The company’s 50 day moving average is $5.53 and its 200 day moving average is $4.69. The firm’s market capitalization is $513.54 million.

Raptor Pharmaceutical Corp. (NASDAQ:RPTP) last released its earnings results on Thursday, May 5th. The company reported ($0.17) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.17). The firm had revenue of $27.47 million for the quarter, compared to analysts’ expectations of $27.17 million. During the same quarter in the previous year, the company posted ($0.24) earnings per share. The firm’s quarterly revenue was up 34.3% on a year-over-year basis. On average, equities analysts predict that Raptor Pharmaceutical Corp. will post ($0.98) earnings per share for the current year.

A hedge fund recently raised its stake in Raptor Pharmaceutical Corp. stock. Cornerstone Capital Management Holdings LLC. boosted its position in Raptor Pharmaceutical Corp. (NASDAQ:RPTP) by 319.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 251,803 shares of the company’s stock after buying an additional 191,703 shares during the period. Cornerstone Capital Management Holdings LLC. owned approximately 0.30% of Raptor Pharmaceutical Corp. worth $1,310,000 at the end of the most recent reporting period.

Raptor Pharmaceutical Corp. is a biopharmaceutical company. The Company is focused on developing and commercializing transformative treatments for people affected by rare and debilitating diseases. The Company’s product, PROCYSBI delayed-release capsules received marketing approval from the FDA for the management of nephropathic cystinosis in adults and children six years and older.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.